Neuroscience specialist Harmony Biosciences has agreed to acquire Zynerba, adding its cannabidiol (CBD) gel product Zygel for Fragile X syndrome and other rare neuropsychi
Self-funded, non-profit medical research organisation and charity LifeArc has announced today that it is to launch the Rare Disease Translational Challenge, which will inv
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.